**Immuno-oncology/Tyrosine Kinase Inhibitor Combination Therapies for the Treatment of Advanced Renal Cell Carcinoma:**

**Which of Your Patients May Benefit from Their Use in the Firstline Setting?**

|  |  |
| --- | --- |
| Resource | Address |
| Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2018;36:1714-1768. | <https://pubmed.ncbi.nlm.nih.gov/29442540/> |
| Cao G, Wu X, Wang Z, et al. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. *BMJ Open*. 2020;10:e034626. | <https://pubmed.ncbi.nlm.nih.gov/32859659/> |
| Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. *Immunity*. 2013;39:1-10. | <https://pubmed.ncbi.nlm.nih.gov/23890059/> |
| Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*. 2021;384:829-841. | <https://pubmed.ncbi.nlm.nih.gov/33657295/> |
| Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. *Lancet Oncol*. 2013;14:141-148. | <https://pubmed.ncbi.nlm.nih.gov/23312463/> |
| Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. *Nat Rev Clin Oncol*. 2019;16:621-633. | <https://pubmed.ncbi.nlm.nih.gov/30992569/> |
| Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. *Eur J Cancer*. 2016;54:139-148. | <https://pubmed.ncbi.nlm.nih.gov/26765102/> |
| Motzer RJ, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. *N Engl J Med*. 2021;384:1289-1300. | <https://pubmed.ncbi.nlm.nih.gov/33616314/> |
| Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med.* 2019:380:1103-1115. | <https://pubmed.ncbi.nlm.nih.gov/30779531/> |
| Osawa T, Takeuchi A, Kojima T, Shinohara N, Eto M, Nishiyama H. Overview of current and future systemic therapy for metastatic renal cell carcinoma. *Jpn J Clin Oncol*. 2019;49:395-403. | <https://pubmed.ncbi.nlm.nih.gov/30722031/> |
| Palapattu GS, Kristo B, Rajfer. Paraneoplastic syndromes in urologic malignancy: The many faces of renal cell carcinoma. *Rev Urol*. 2002;4:163-170. | <https://pubmed.ncbi.nlm.nih.gov/16985675/> |
| Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2020;21:1563-1573. | <https://pubmed.ncbi.nlm.nih.gov/33284113/> |
| Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *J Immunother Cancer*. 2017;5:95. | <https://pubmed.ncbi.nlm.nih.gov/29162153/> |
| Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*. 2019;380:1116-1127. | <https://pubmed.ncbi.nlm.nih.gov/30779529/> |
| Sanchez-Gastaldo A, Kempf E, González Del Alba A, Dura. Systemic treatment of renal cell cancer: A comprehensive review. *Cancer Treat Rev*. 2017;60:77-89. | <https://pubmed.ncbi.nlm.nih.gov/28898679/> |
| Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. *J Clin Oncol*. 2015;33:2092-2099. | <https://pubmed.ncbi.nlm.nih.gov/25918278/> |
| Zerdes I, Tolia M, Tsoukalas N, et al. Systemic therapy of metastatic renal cell carcinoma: Review of the current literature. *Urologia*. 2019;86:3-8. | <https://pubmed.ncbi.nlm.nih.gov/30270773/> |

**Resources and Societies**

|  |  |
| --- | --- |
| Resource | Address |
| American Association for Cancer Research (AACR). | <https://www.aacr.org/> |
| American Cancer Society (ACS). Kidney Cancer. | <https://www.cancer.org/cancer/kidney-cancer.html> |
| American Society of Clinical Oncology (ASCO). | <https://www.asco.org/> |
| European Society for Medical Oncology (ESMO). | <https://www.esmo.org/> |
| Kidney Cancer Association. | <https://www.kidneycancer.org/> |
| National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 3.2022. Published November 4, 2021. | <https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf> |